CA
ZVRA icon

Clearstead Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Clearstead Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Buy
+3
New +$33 ﹤0.01% 3501
2026
Q1 		– Sell
-1
Closed -$9 – 2874
2025
Q4 		$9 Hold
1
– – ﹤0.01% 2716
2025
Q3 		$10 Buy
+1
New +$10 ﹤0.01% 3047

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Clearstead Advisors's ZVRA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 3 shares worth $44. The stake represents ﹤0.01% of the portfolio and ranks #3501 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ZVRA as recently as Q4 2025.

Clearstead Advisors first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. 54 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Clearstead Advisors held 3 shares of Zevra Therapeutics worth $44 as of Q2 2026.
  • Zevra Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3501 holding.
  • Clearstead Advisors first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 54 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.